Inotropic Agent Market Statistics 2028 -
Inotropic agent is a medicine responsible for changing the force of the heart's contractions. These agents are of two types, positive inotropic agent and negative inotropic agents. Positive inotropic agents strengthen the force of the heart resulting in an increased heartbeat. On the other hand, negative inotropic agents weaken the force of the heart causing a decrease in heartbeats. Both these types of inotropes are used in the treatment of various cardiovascular conditions, including hypertension, cardiomyopathy (congestive heart failure), arrhythmias (abnormal heart rhythms), angina (chest pain), and chronic heart failure.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the inotropic agent market.
Top Impacting Factors
Rise in prevalence of heart diseases and heart surgeries all across the globe is one of the factors that will drive the ionotropic agent market during the forecast period.
In addition, with a change in lifestyle, high number of people suffering from hypertension. Ionotropic agents are often used to control such conditions, which is influencing the inotropic agent market growth positively.
Negative inotropes weaken the contraction of the heart. Hence, they are useful in treating a variety of cardiac diseases such as abnormal heart rhythms, angina (chest pain), and chronic heart failure. With such a broad usage, these inotropes are expected to gain a significant share in the market, thus propelling the market growth.
However, novel inotropic agents in the market are losing their patents’ exclusivity. This can set a trend for the introduction of generic medicines, which is expected to impede the growth of original inotropic agents market.
Key Market Trends
North America acquires the largest share in the inotropic agent market, as the pharmaceutical organizations in this region are taking various initiatives to generate novel formulations of inotropic agents.
Asia-Pacific is anticipated to account for the largest market share during the forecast period, due to increase in cases of diabetes and hypertension along with rise in prevalence of cardiac diseases.
Some prominent players in the inotropic agents market are implementing different strategies, which include making acquisitions and launching new products. This is helping them consolidate their positions in the global inotropic agent market.
Moreover, a steep rise in availability of public funding for the development of inotropic agents is fueling the market. Some of the companies that dominate the inotropic agent market are Maybe Pharma Group Ltd., Janssen Pharmaceuticals, Inc., and Johnson and Johnson Services, Inc.
Key Benefits of the Report
- This study presents the analytical depiction of the inotropic agent industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the inotropic agent market share.
- The current market is quantitatively analyzed to highlight the inotropic agent market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Inotropic Agent Report
- Which are the leading players active in the inotropic agent market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the inotropic agent market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is an inotropic agent?
- What is the inotropic agent market prediction in the future?
- What are the current trends and predicted trends?
Inotropic Agent Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Indication |
|
 By Route of Administration |
|
 By End User |
|
 By DISTRIBUTION CHANNEL |
|
 By Region |
|
 Key Market Players | Pfizer Inc., Hikma Pharmaceuticals PLC., GlaxoSmithKline Plc., Sun Pharmaceuticals Industries Ltd., Mylan N.V., Fresenius Kabi USA., Baxter, Sanofi, Covis Pharma, Eli Lilly and Company |
Loading Table Of Content...
